Kerrigan Dennis Francis
Known title: Executive Vice PresidentCIK: 0001799888
Associated companies
Transaction History
| THG | ▲ Buy | Grant | 15 | $0 | 9/25/2026 | View on chart |
| THG | ▲ Buy | Option Exercise | 2,104 | $249K | 8/20/2026 | View on chart |
| THG | ▼ Sell | Open Market | 400 | $88K | 8/20/2026 | View on chart |
| THG | ▼ Sell | Open Market | 1,704 | $380K | 8/20/2026 | View on chart |
| THG | ▲ Buy | Option Exercise | 6,551 | $777K | 8/19/2026 | View on chart |
| THG | ▼ Sell | Open Market | 4,822 | $1.1M | 8/19/2026 | View on chart |
| THG | ▼ Sell | Open Market | 1,505 | $334K | 8/19/2026 | View on chart |
| THG | ▼ Sell | Open Market | 224 | $50K | 8/19/2026 | View on chart |
| THG | ▲ Buy | Grant | 15 | $0 | 6/26/2026 | View on chart |
| THG | ▲ Buy | Option Exercise | 6,262 | $722K | 5/20/2026 | View on chart |
| THG | ▼ Sell | Open Market | 6,262 | $1.2M | 5/20/2026 | View on chart |
| THG | ▲ Buy | Grant | 19 | $0 | 3/27/2026 | View on chart |
| THG | ▼ Sell | Tax Withholding | 1,751 | $316K | 2/27/2026 | View on chart |
| THG | ▲ Buy | Grant | 1,730 | $0 | 2/24/2026 | View on chart |
| THG | ▲ Buy | Grant | 1,115 | $0 | 2/24/2026 | View on chart |
| THG | ▲ Buy | Grant | 1,117 | $0 | 2/24/2026 | View on chart |
| THG | ▲ Buy | Grant | 17 | $0 | 12/26/2025 | View on chart |
| THG | ▼ Sell | Tax Withholding | 150 | $28K | 12/1/2025 | View on chart |
| THG | ▼ Sell | Gift | 175 | $0 | 11/4/2025 | View on chart |
| THG | ▲ Buy | Grant | 18 | $0 | 9/26/2025 | View on chart |
| THG | ▲ Buy | Grant | 19 | $0 | 6/27/2025 | View on chart |
| THG | ▲ Buy | Grant | 18 | $0 | 3/28/2025 | View on chart |
| THG | ▼ Sell | Tax Withholding | 1,180 | $201K | 2/28/2025 | View on chart |
| THG | ▲ Buy | Grant | 1,082 | $0 | 2/25/2025 | View on chart |
| THG | ▲ Buy | Grant | 1,328 | $0 | 2/24/2025 | View on chart |
| THG | ▲ Buy | Grant | 243 | $0 | 2/24/2025 | View on chart |
| THG | ▲ Buy | Grant | 20 | $0 | 12/27/2024 | View on chart |
| THG | ▲ Buy | Grant | 20 | $0 | 9/27/2024 | View on chart |
| THG | ▲ Buy | Grant | 23 | $0 | 6/28/2024 | View on chart |
| THG | ▲ Buy | Grant | 21 | $0 | 3/28/2024 | View on chart |
| THG | ▲ Buy | Grant | 1,211 | $0 | 2/27/2024 | View on chart |
| THG | ▲ Buy | Grant | 1,369 | $0 | 2/26/2024 | View on chart |
| THG | ▲ Buy | Grant | 949 | $0 | 2/26/2024 | View on chart |
| THG | ▼ Sell | Tax Withholding | 1,055 | $142K | 2/26/2024 | View on chart |
| THG | ▲ Buy | Grant | 23 | $0 | 12/29/2023 | View on chart |
| THG | ▲ Buy | Grant | 24 | $0 | 9/29/2023 | View on chart |
| THG | ▲ Buy | Grant | 24 | $0 | 6/30/2023 | View on chart |
| THG | ▲ Buy | Grant | 21 | $0 | 3/31/2023 | View on chart |
| THG | ▼ Sell | Tax Withholding | 1,092 | $152K | 2/28/2023 | View on chart |
| THG | ▲ Buy | Grant | 1,470 | $0 | 2/27/2023 | View on chart |
| THG | ▲ Buy | Grant | 1,078 | $0 | 2/27/2023 | View on chart |
| THG | ▲ Buy | Grant | 1,072 | $0 | 2/27/2023 | View on chart |
| THG | ▲ Buy | Grant | 20 | $0 | 12/30/2022 | View on chart |
| THG | ▲ Buy | Grant | 19 | $0 | 9/30/2022 | View on chart |
| THG | ▲ Buy | Grant | 17 | $0 | 6/24/2022 | View on chart |
| THG | ▲ Buy | Grant | 16 | $0 | 3/25/2022 | View on chart |
| THG | ▲ Buy | Grant | 986 | $0 | 2/28/2022 | View on chart |
| THG | ▲ Buy | Grant | 13 | $0 | 12/30/2021 | View on chart |
| THG | ▲ Buy | Grant | 12 | $0 | 9/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Hanover Insurance (THG) Draws Attention for Growth and Valuation
Recent articles highlight Hanover Insurance as a potential growth candidate, citing strong capital allocation and a discounted valuation. These reports suggest the stock may be undervalued relative to its fundamentals. The company is currently trading near its 52-week high, with an average analyst target price of $235.88.
Hanover Insurance (THG) Draws Attention for Growth and Valuation. Recent articles highlight Hanover Insurance as a potential growth candidate, citing strong capital allocation and a discounted valuation. These reports suggest the stock may be undervalued relative to its fundamentals. The company is currently trading near its 52-week high, with an average analyst target price of $235.88.